Clinical trial data management, biometrics and analytics services for sponsors
Atorus is a clinical data and biometrics services firm whose stack straddles legacy SAS (Enterprise Guide, Viya) and an open-source R ecosystem (Shiny, tidyverse, Posit Connect) running on AWS EKS and Kubernetes. Job posts point to a SAS production upgrade alongside CI/CD and cloud infrastructure design, while recurring pain around external vendor data discrepancies shows data acquisition quality is a core operational pressure.
Atorus provides clinical data management, biometrics and analytics services to organizations running clinical trials. Its work spans collecting and reconciling trial data, automating routine statistical programming, and visualizing clinical results in standards-compliant formats such as CDISC. Teams work with EDC platforms including Medidata Rave and Veeva CDMS, and support studies from phase 1 through phase 3. The privately held company employs 201–500 people, is headquartered in Newtown Square, PA, and hires across the United States, India, Costa Rica, Germany and France.
Atorus uses SAS (Enterprise Guide, Viya), R tools like Shiny, tidyverse and Posit Connect, Python, Medidata Rave, Veeva CDMS, CDISC standards, and AWS infrastructure including EKS, Docker and Kubernetes.
Atorus is headquartered in Newtown Square, Pennsylvania, and hires in the United States, India, Costa Rica, Germany and France.
Yes. Engineering and data roles lead Atorus's hiring mix, focused on CI/CD pipelines, cloud infrastructure and SAS environment upgrades, though overall hiring velocity is decelerating.
Other companies in the same industry, closest in size
Atorus's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.